FATE THERAPEUTICS INC Cash Flow Statement
FATE|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
FATE THERAPEUTICS INC used $123M in operating cash flow and negative free cash flow of $124M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$186.3M | -$160.9M | -$281.7M | -$173.4M | -$98.1M | -$66.6M | -$43.0M | -$33.5M | -$30.0M | -$25.9M | -$20.9M | -$14.2M | -$1.2M |
| Depreciation & Amortization | $19.0M | $18.3M | $13.8M | $3.1M | $2.2M | $1.2M | $971.0K | $881.0K | $687.0K | $496.0K | $571.0K | $590.0K | $672.0K |
| Operating Cash Flow | -$122.9M | -$132.3M | -$248.2M | -$39.2M | -$83.2M | -$38.6M | -$36.8M | -$29.8M | -$18.4M | -$22.4M | -$15.4M | -$13.3M | -$12.1M |
| Capital Expenditures | $730.0K | $6.2M | $35.6M | $4.9M | $7.4M | $2.3M | $1.7M | $457.0K | $1.5M | $882.0K | $244.0K | $709.0K | $2.0K |
| Free Cash Flow | -$123.6M | -$138.4M | -$283.8M | -$44.2M | -$90.6M | -$41.0M | -$38.5M | -$30.3M | -$19.9M | -$23.3M | -$15.6M | -$14.0M | -$12.1M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | $7.0K |
| FCF Margin | -906.8% | -217.9% | -294.7% | -140.5% | -848.0% | -864.0% | -938.7% | -687.9% | - | -1762.6% | -1608.3% | -523.7% | -1038.2% |